You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
Escher is an independent, international research platform, with a pan-European focus. Escher builds on the results and track-record of the TI Pharma's Escher FES project. Today, Escher is TI Pharma's multi-stakeholder platform for research in regulatory and HTA topics to advance the development of socially valuable medicines.
A more efficient and effective regulatory system can help to better address medical needs by speeding up the development of innovative medicines and medical technology, while assuring safety and contributing to a better management of public expenditures on healthcare. Escher focuses on four research topics:
Currently, Escher is working on a project called "Improving the EU system for marketing authorization: Reviewing regulatory deficiencies and inefficiencies". It aims to:
More information can be found on the Escher website.
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board